The relationship between serum biomarkers NfH, NOx, GFAP, BDNF, NGF and clinical (MSFC, EDSS, MSIS-29) as well as MRI measures are presented in tabular form and as forest plots.

<p>a) 25-foot walk (secs); b) 9-hole peg test, dominant had (secs); c) 9-hole peg test, non-dominant hand (secs); d) Paced Auditory Serial Addition Test (PASAT); e) Z-score; f) Expanded Disability Status Scale (EDSS); g) Multiple Sclerosis Impact Scale (MSIS-29) physical; h) MSIS-29 psychological; i) Magnetization Transfer Ratio (MTR) white matter; j) MTR grey matter; k) MTR whole brain; l) MRI Central Cerebral Volume (MRICCV); m) T1 volume; n) T2 volume.</p

Survival curves of walking times and 9-hole peg test times (dominant and non-dominant hand) are plotted according to absent, below median or above median NfH levels.

<p>Survival curves of walking times and 9-hole peg test times (dominant and non-dominant hand) are plotted according to absent, below median or above median NfH levels.</p

Summary characteristics of subjects in the study according to randomisation, serum adherence and tablet compliance (p>0.05).

<p>Three samples were present in each sub-group corresponding to time points 0–12–24 months *, and of the 120 subjects who participated in the biomarker study there were 19 drop-outs ^†.</p

Power curves for determining sample size for changes percentage change in NfH levels.

<p>Power curves for determining sample size for changes percentage change in NfH levels.</p

A diagrammatic representation of patient follow up and investigations.

<p>CSF sampling was performed at 6 and 18 m in 9 subjects and 12 m in 14 subjects.</p